The Partners PrEP Study and the CDC's TDF2 study found significant reductions in HIV infections among participants taking antiretroviral drugs. The VOICE study will continue to evaluate the effectiveness of oral pre-exposure prophylaxis, with a focus on its impact on women and the optimal treatment approach.
A new clinical trial is being conducted to evaluate the safety of a promising HIV prevention gel, tenofovir gel, in pregnant and breastfeeding women. The study aims to provide critical information on the safety of using tenofovir gel during pregnancy and lactation.
A Phase II trial found that tenofovir gel achieved a more than 100-times higher concentration of active drug in vaginal tissue compared to the oral tablet. Most US women preferred the oral tablet, while African women favored the gel and tablet equally. The study's findings will be better understood in the context of VOICE results.
Researchers have reformedulated tenofovir gel to make it safe and effective for rectal use, with laboratory tests showing reduced harm to the lining of the rectum and comparable HIV protection. The reformulated gel is now being tested in clinical trials to address concerns about comfort and side effects.
A study found that tenofovir gel provided significant protection against HIV in rectal tissue, with a strong effect seen after one week of use. The results suggest that rectal microbicides could be an effective method for preventing HIV transmission, particularly in high-risk populations.
A clinical trial known as iPrEx found that taking antiretroviral drugs daily can significantly reduce the risk of HIV infection among men who have sex with men. The study involved 2,499 participants and showed a nearly 44% lower rate of HIV infections in those taking the drug.
Researchers testing tenofovir gel's rectal safety in a new trial led by the NIH-funded Microbicide Trials Network. The study aims to determine if rectal use of tenofovir gel is safe and effective in preventing HIV transmission among men and women who engage in receptive anal intercourse.
A recent study found that using a vaginal microbicide with an antiretroviral drug called tenofovir significantly reduced HIV infections among women. The study involved 889 women from South Africa and found that those who used the gel before and after sex had 39% fewer HIV infections compared to those who used a placebo gel.
The VOICE study aims to evaluate the safety and effectiveness of two ARV regimens: daily vaginal gel and daily oral tablets, to reduce HIV risk in women. The trial will enroll up to 5,000 participants across four countries and assess their willingness to use the methods.
Researchers are comparing the effectiveness of tenofovir as an oral tablet and vaginal gel for HIV prevention. The study aims to understand how each formulation works in infection-prone cells, with a focus on optimal doses and women's adherence.
A clinical trial is investigating the safety of a vaginal microbicide gel for pregnant women and their babies. The study aims to understand how pregnancy affects the body's absorption of the active drug and whether it can be transferred to the fetus.
A Phase II study has shown that tenofovir gel is safe for daily use and most women adhere to the regimen, suggesting a potential new approach to preventing HIV transmission. The findings are significant for women who are at high risk of infection due to heterosexual intercourse.
A new vaginal microbicide, VivaGel, is being tested in a clinical safety trial among sexually active young women to determine its safety and acceptability. The study aims to assess the product's effectiveness in preventing HIV transmission and gather information on user experience.
The Microbicide Trials Network will conduct 17 clinical trials over seven years to determine if topical microbicides can prevent the sexual transmission of HIV in women. The network, supported by NIH, brings together international investigators and community partners to develop and evaluate microbicides.